Bruce Feinberg, DO; Scott Gottlieb, MD; and Ted Okon, MBA, discuss the intentions and overall impact of the 340B Drug Pricing Program on the healthcare industry.
Dr Gottlieb and Mr Okon explain that despite its good intentions, the 340B Drug Pricing Program is leading to consolidation between oncology practices and hospitals.
“A program that was meant to service hospitals that really did have diverse missions and really did service a lot of underprivileged patients has been exploited by hospitals that don’t necessarily have the same mission,” says Dr Gottlieb.
Dr Gottlieb discusses further how hospitals are exploiting the program to generate additional revenue. He also explains that this consolidation is forcing some patients to receive oncology care in a hospital setting, which is not always best. This consolidation drives up healthcare costs and can affect the overall quality of care for patients.
Mr Okon notes that specifically, disproportionate-share hospitals are affecting the success of the 340B Drug Pricing Program, and highlights figures that demonstrate the overall financial impact of this program in the oncology setting.
Patient Care Experience Declines After Private Equity Hospital Acquisitions
January 31st 2025Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in overall hospital ratings, willingness to recommend, and staff responsiveness.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More